Manufacturing scale will influence how quickly the market expands, while effective oral GLP-1 therapies could broaden prescribing between 2026 and 2030
In some cases, temporary dose reduction or pausing dose escalation of the GLP-1 medication may be appropriate while nutritional status is optimized, though this decision should be made collaboratively between patient and provider
Three groups were identified: participants with current MDD (that is, participants meeting DSM-IV criteria for MDD within the past 6 months), with remitted (i.e., lifetime but not current) MDD, and healthy controls (without any lifetime depressive/anxiety disorder)
While the exact mechanisms are unclear, maintaining regular communication with your healthcare provider can help manage any potential risks
Our approach focuses on helping you understand your body, identify contributing factors, and create a realistic plan that fits your lifestyle and goals